SCHEMBL9949587

SCHEMBL9949587

CC(C)(C)OC(=O)C1CCC(=O)CN1C(=O)O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.37
HDAC1 Q13547 4/20 0.34
HDAC8 Q9BY41 4/20 0.34
HDAC6 Q9UBN7 4/20 0.34
BTK Q06187 1/20 0.33
HDAC5 Q9UQL6 1/20 0.33
CASP3 P42574 1/20 0.32
HSD17B10 Q99714 2/20 0.32
KLK7 P49862 1/20 0.32
ROCK2 O75116 1/20 0.32
HRH3 Q9Y5N1 1/20 0.31
MMP2 P08253 1/20 0.31
ANPEP P15144 1/20 0.31
NFKB1 P19838 1/20 0.31
NFKB2 Q00653 1/20 0.31
RELA Q04206 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
GLA P06280 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL717566 0.88 PTPN1 (0.38) MAPK1HDAC8HSD17B10KLK7KDM4E
SCHEMBL721105 0.88 PTPN1 (0.38) MAPK1HDAC8HSD17B10KLK7KDM4E
SCHEMBL19900653 0.83 MMP2 (0.43) MMP2ANPEPALDH1A1KMT2A
SCHEMBL22654848 0.81 FKBP1A (0.37)
SCHEMBL5761827 0.79 PTPN1 (0.46) HDAC8HSD17B10MMP2ANPEPKDM4E
SCHEMBL10058225 0.79 PTPN1 (0.46) HDAC8HSD17B10MMP2ANPEPKDM4E
SCHEMBL22543468 0.79 PTPN1 (0.46) HDAC8HSD17B10MMP2ANPEPKDM4E
SCHEMBL19566140 0.79 NPC1 (0.38) HDAC8HSD17B10KDM4ECHRM2CHRM1
SCHEMBL4497625 0.79 HSD17B10 (0.43) BTKHSD17B10CHRM2CHRM1CHRM3
SCHEMBL717567 0.79 HSD17B10 (0.43) BTKHSD17B10CHRM2CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230331724-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2023-10-19 US disclosed
US-11731971-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2023-08-22 US disclosed
US-20210371419-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2021-12-02 US disclosed
US-11117896-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2021-09-14 US disclosed
US-20200048253-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2020-02-13 US disclosed
US-10556905-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2020-02-11 US disclosed
EP-2857401-B1 NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME MEIJI SEIKA PHARMA CO LTD (JP) 2019-09-18 EP disclosed
US-20180258089-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2018-09-13 US disclosed
US-10023573-B2 Beta-lactamase inhibitor and process for preparing the same MEIJI SEIKA PHARMA CO., LTD. (JP) 2018-07-17 US disclosed
US-20170233393-A1 BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME MEIJI SEIKA PHARMA CO., LTD. (JP) 2017-08-17 US disclosed
US-20160024090-A1 BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME MEIJI SEIKA PHARMA CO., LTD. (JP) 2016-01-28 US disclosed
US-9181250-B2 Beta-lactamase inhibitor and process for preparing the same MEIJI SEIKA PHARMA CO., LTD. (JP) 2015-11-10 US disclosed
US-20150239840-A1 COMPOUNDS USEFUL FOR PRODUCING AN OPTICALLY ACTIVE DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2015-08-27 US disclosed
US-20150141401-A1 NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME MEIJI SEIKA PHARMA CO., LTD. (JP) 2015-05-21 US disclosed
US-9035062-B2 Process for preparing a compound useful for producing an optically active diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2015-05-19 US disclosed
EP-2857401-A1 NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME Meiji Seika Pharma Co., Ltd. (JP) 2015-04-08 EP disclosed
US-20140303375-A1 PROCESS FOR PREPARING A COMPOUND USEFUL FOR PRODUCING AN OPTICALLY ACTIVE DIAZABICYCLOOCTANE COMPOUND Meiji Seika Pharma. Co., Ltd. (JP) 2014-10-09 US disclosed
US-8772490-B2 Optically active diazabicyclooctane derivatives and process for preparing the same MEIJI SEIKA PHARMA CO., LTD. (JP) 2014-07-08 US disclosed
EP-2657234-A1 OPTICALLY-ACTIVE DIAZABICYCLOOCTANE DERIVATIVE AND METHOD FOR MANUFACTURING SAME Meiji Seika Pharma Co., Ltd. (JP) 2013-10-30 EP disclosed
US-20120165533-A1 OPTICALLY ACTIVE DIAZABICYCLOOCTANE DERIVATIVES AND PROCESS FOR PREPARING THE SAME MEIJI SEIKA PHARMA CO., LTD. (JP) 2012-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731971-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 MAPK1 472/4885HDAC1 2457/4885HDAC8 4318/4885
US-20200048253-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 MAPK1 472/4885HDAC1 2457/4885HDAC8 4318/4885
US-20120165533-A1 OPTICALLY ACTIVE DIAZABICYCLOOCTANE DERIVATIVES AND PROCESS FOR PREPARING THE SAME DCXR, CBR1, DECR1 MAPK1 2821/4885HDAC1 3082/4885HDAC8 3001/4885
US-20160024090-A1 BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME ME1, MRPL21, FNTB MAPK1 2176/4885HDAC1 310/4885HDAC8 1206/4885
US-20140303375-A1 PROCESS FOR PREPARING A COMPOUND USEFUL FOR PRODUCING AN OPTICALLY ACTIVE DIAZABICYCLOOCTANE COMPOUND TBC1D15, TBC1D5, TERT MAPK1 607/4885HDAC1 384/4885HDAC8 424/4885
US-20150141401-A1 NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME ME1, FN1, FNTB MAPK1 1587/4885HDAC1 460/4885HDAC8 1442/4885
US-20210371419-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 MAPK1 472/4885HDAC1 2457/4885HDAC8 4318/4885
US-20150239840-A1 COMPOUNDS USEFUL FOR PRODUCING AN OPTICALLY ACTIVE DIAZABICYCLOOCTANE COMPOUND TERT, TBC1D5, TBC1D15 MAPK1 2488/4885HDAC1 233/4885HDAC8 298/4885
US-20180258089-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 MAPK1 472/4885HDAC1 2457/4885HDAC8 4318/4885
US-10023573-B2 Beta-lactamase inhibitor and process for preparing the same FN1, FNTB, CPN1 MAPK1 1429/4885HDAC1 1593/4885HDAC8 3853/4885
US-20230331724-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 MAPK1 472/4885HDAC1 2457/4885HDAC8 4318/4885
US-10556905-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 MAPK1 472/4885HDAC1 2457/4885HDAC8 4318/4885
US-20170233393-A1 BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME FN1, FNTB, CPN1 MAPK1 1429/4885HDAC1 1593/4885HDAC8 3853/4885
US-11117896-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 MAPK1 472/4885HDAC1 2457/4885HDAC8 4318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.